| 郭晓东1 熊璐1 杨坤1 丁宁1 郝晓刚1 吉英杰1 田如意1 孙婷2.阿德福韦酯联合乙肝免疫球蛋白预防HBV 相关性终末期肝病肝移植术
后复发的临床研究[J].,2011,11(11):2122-2124 |
| 阿德福韦酯联合乙肝免疫球蛋白预防HBV 相关性终末期肝病肝移植术
后复发的临床研究 |
| Effects of Adefovir Dipivoxil plus Hepatitis B Immunoglobulin in Preventionof HBV Recurrence in Patients with HBV-related End-stage Liver Diseaseafter Liver Transplantation |
| |
| DOI： |
| 中文关键词: 肝移植 HBV 复发 阿德福韦酯 拉米夫定 乙肝免疫球蛋白 |
| 英文关键词: Liver transplantation Hepatitis B virus recurrence Adefovir dipivoxil Lamivudine Hepatitis B immunoglobulin |
| 基金项目: |
|
| 摘要点击次数: 660 |
| 全文下载次数: 897 |
| 中文摘要: |
| 目的：探讨阿德福韦酯（HDV）联合乙肝免疫球蛋白（HBIg）预防HBV 相关性终末期肝病患者肝移植术后HBV 复发的临床
疗效。方法：回顾性分析2005 年6 月～2009 年6 月北京市解放军第302 医院因HBV 相关性终末期肝病接受肝移植的60 例患者
的临床资料。60 例患者根据治疗方法分为治疗组和对照组，治疗组采用HDV 联合HBIg 预防肝移植术后HBV 复发，对照组采用
拉米夫定（LAM）联合HBIg 预防HBV 复发。结果：两组患者随访期内未出现肾毒性表现。治疗组平均随访时间为（21. 67±5. 37）
月，随访期内无复发。对照组平均随访时间为（21. 83±6. 02）月，随访期内有2 例复发。两组术后复发率比较有显著性差异（P<0.
05）。结论：HDV 联合HBIg 预防肝移植术后HBV 复发近期疗效优于LAM 联合HBIg。 |
| 英文摘要: |
| Objective: To investigate the effect of adefovir dipivoxil (ADV) combined with hepatitis B immunoglobulin (HBIg)
therapeutics on prevention of hepatitis B virus (HBV) recurrence in patients with HBV-related end-stage liver disease after liver transplantation
(LT). Methods: 60 cases with HBV-related end-stage liver disease of LT were chosen. 60 patients were divided into treatment
group and control group according to different therapeutics. The patients of the treatment group was given ADV combined with HBIg
therapeutics to prevent HBV recurrence, while the patients of the control group was given lamivudine(LAM) combined with HBIg therapeutics
to prevent HBV recurrence. Results: The patients of the two groups were no renal toxicity during the follow-up time. The average
follow-up time of the treatment group was (21.67 ± 5.37) months, there was no HBV recurrence during the follow-up time. The average
follow-up time of the control group was (21.83 ± 6.02) months, there was 2 cases of HBV recurrence during the follow-up time. The
HBV recurrence rate of the two groups was significantly different (P <0.05). Conclusion: The ADV combined with HBIg therapeutics
was better than LAM combined with HBIg therapeutics to prevent HBV recurrence in patients with HBV-related end-stage liver disease
after LT for the near term. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
